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Abstract
Background and Objective—To measure the subfoveal choroidal thickness in patients with
age-related macular degeneration (AMD) over 6 months.
Study Design/Patients and Methods—A retrospective, observational study of patients with
AMD followed for 6 months at the New England Eye Center. Baseline and 6 month subfoveal
choroidal thickness was measured using spectral domain OCT and compared.
Results—For the entire cohort there was statistically significant thinning of the subfoveal
choroidal thickness at 6 months compared to baseline, which was driven by the cohort of patients
with neovascular AMD [181.2 +/− 75 μm to 173.4 +/− 63 μm] p=0.049. (Figure and Table 1).
Conclusions—There was a statistically significant decrease in subfoveal choroidal thickness
observed in this cohort of patients with AMD over 6 months, but it was driven by one subgroup,
those patients with neovascular age related macular degeneration.
Introduction
OCT provides cross-sectional, three-dimensional, high resolution views of the retina in vivo
in a non-invasive, reproducible manner.1 Spectral domain (SD) OCT permits fast scanning
speeds of up to 52,000 A-scans/second, and with improvements in SD OCT technology such
as image averaging, and enhanced depth imaging (EDI), imaging through the choroid is now
possible.2-6 The choroidal thickness has been evaluated using SD OCT in both normal and
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diseased states such as in patients with high myopia, age related macular degeneration
(AMD), central serous chorioretinopathy (CSCR), and age-related choroidal atrophy. 7-10
AMD is the leading cause of irreversible visual impairment among the elderly
worldwide.11-12 OCT generated macular thickness maps have proven useful in monitoring
the progression and response to treatment in neovascular AMD (nAMD) after anti-vascular
endothelial growth factor (VEGF) treatment, and more recently, SD OCT and enhanced
depth imaging (EDI) are being used to examine the choroid of patients with AMD.10,13,14
Choroidal thinning has been described in patients with AMD compared to age-matched
controls, however there has not been significant investigation regarding the change in the
subfoveal choroid thickness of AMD patients over time.10, 15, 16 The purpose of this study is
to examine the change in subfoveal choroidal thickness in patients with neovascular AMD
(nAMD) and dry AMD over a 6 month time period using SD OCT.
Study Design/Patients and Methods
This is a retrospective observational study investigating the change in subfoveal choroidal
thickness in patients with both neovascular and dry AMD over a time period of 6 months.
This study was approved by the Institutional Review Board of Tufts Medical Center, and
was conducted in adherence to the tents of the Declaration of Helsinki. Patients previously
diagnosed with AMD who were followed for 6 months at the New England Eye Center,
Tufts Medical Center, between 11/2009-11/2010 were included in this study. All patients
included in this study underwent a comprehensive ophthalmologic examination with fundus
biomicroscopy, color fundus photography, best corrected Snellen visual acuity, and OCT
imaging. OCT imaging was performed using Cirrus-HD OCT software version 4.5. The
software version allows for the acquisition of high-definition 1-line raster scans that are
constructed from 20 B-scans obtained at the same location and processed using a unique
Selective Pixel Profiling system (Cirrus HD-OCT; Carl Zeiss Meditec.). The 1-line raster
scan, which is a 6 mm line scan consisting of 4096 A-scans, has an axial resolution of 5-6
um and a transverse resolution of 15-20 um. Images were taken with the vitreoretinal
interface adjacent to the zero-delay, and were not inverted to bring the choroid adjacent to
zero-delay, as image inversion using the Cirrus software results in a low-quality image.
These high definition images provide increased definition of retinal layers, as well as more
posterior structures, such as the choroid-sclera junction. All reviewed scans had an intensity
of 6/10 or greater, were taken as close to the fovea as possible, with adequate visualization
of the choroid-sclera boundary.
The subfoveal choroidal thickness was measured manually using the Cirrus linear
measurement tool (version 4.5, Carl Zeiss Meditec, Dublin, CA). The measurements were
taken from the base of the hyperreflective retinal pigment epithelium to the hyporeflective
line corresponding to the sclera-choroidal interface junction. The same scan was used for all
patients and the readers were masked from each other's results. Two measurements were
taken at baseline and at 6 months by three independent observers, (J.F., V.M., L.B) and the
average data were compared for each patient. Chart review was performed to collect
information regarding duration of disease, number of intravitreal anti-VEGF injections,
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visual acuity (VA), and concomitant retinal pathology. Highly myopic patients (> 6 D) were
excluded secondary to known choroidal thinning.8
The results were also compared with age-matched controls, using data from a previous study
by this same group. All statistics were calculated using SPSS software version 17.0 for
Windows (SPSS, Inc, Chicago, Illinois, USA). The paired t-test was used to correlate mean
subfoveal choroidal thickness values at baseline and at 6 months. Data are expressed as
means ± standard error of the mean (SEM). P values ≤0.05 were considered to be
significant.
Results
Of the initial 65 eyes of 52 patients identified, 16 eyes were excluded secondary to lack of
follow-up, incomplete choroidal penetration on subsequent OCT scans, or follow-up scans
with inadequate signal strength. There was one patient excluded because the outer boundary
of the choroid was not visualized. This patient had a history of neovascular AMD and was
noted to have a scar with fibrosis along with subretinal hemorrhage and intraretinal fluid on
initial enrollment. On subsequent exam, the choroidal scleral boundary was not visualized
secondary to poor penetration through the scar. Patients were sub classified as having dry
AMD if there was no evidence of neovascularization such as intraretinal or subretinal fluid
at any visit time point. This group included patients with geographic atrophy, drusen, and
drusenoid or serous pigment epithelial detachments not associated with choroidal
neovascularization. The dry AMD patients were not further categorized to assess for severity
of disease. Patients were subclassified as having neovascular age related macular
degeneration (nAMD), if there was evidence of neovascularization such as intraretinal or
subretinal fluid at any visit time point. All patients classified with nAMD had subfoveal
neovascularization. Patients were treated by different attending physicians with a
combination of treat and extend and as-needed regimens with anti-VEGF therapy. In total
there were 49 eyes from 39 total patients that had adequate 6 month follow-up, of these 30
eyes (61%) had nAMD, and 19 eyes (39%) had dry AMD. 22 were women (56%) and 17
men (44%), with an average age of 78.5 years (range, 59 to 93 years).
3 patients had one eye included in the dry AMD group and 1 eye included in the nAMD
group. Of the patients with nAMD, no patients were treatment naïve: 23 eyes had received
intravitreal ranibizumab, 12 eyes intravitreal bevacizumab, 2 eyes intravitreal pegaptanib, 1
eye intravitreal triamcinolone, and 5 eyes either photodynamic therapy or laser. Of patients
that received PDT: 2 eyes had one session, 3 eyes 3 sessions, and 1 eye 4 sessions. None of
these sessions were during or shortly before the 6-month period examined in this
investigation. Three of the PDT treated eyes had thinner than average choroidal thickness.
Of the 30 eyes with nAMD, 14 eyes had received between 1-5 injections, 5 eyes between
5-10 injections, and 10 eyes between 11-20 injections prior to enrollment in the study. 10
eyes received a combination of treatments listed above prior to enrollment in the study.
For the entire cohort of AMD patients, there was a statistically significant thinning of the
subfoveal choroidal thickness at six months compared to baseline [181.2 +/− 75 μm to 173.4
Fein et al. Page 3













+/− 63 μm] p=0.049. (Figure and Table 1). This finding was driven by the subgroup of
nAMD patients. In the subgroup of dry AMD eyes, subfoveal choroidal thickness did not
demonstrate statistically significant change between baseline and 6 months [192.2 +/− 70μm
to 190.8 +/−60 μm] p=0.824 (Table 1 and Figures 1 and 2). In the subgroup of nAMD eyes,
there was a statistically significant difference between subfoveal choroidal thickness at
baseline and at 6 month follow-up [182.8 +/− 77μm to 169.1 +/− 62 μm] p = 0.015 (Table 1,
Figures 1 and 3).
In the nAMD group, which consisted of 30 total eyes from 27 total patients, 10 eyes (33%)
demonstrated increased subfoveal choroidal thickness and 20 eyes (66%) demonstrated a
decrease in subfoveal choroidal thickness at 6 month follow-up. The opposite pattern was
observed in the subgroup of dry AMD patients, which consisted of a total of 19 eyes from
14 patients. 12 eyes (63%) demonstrated an increase in subfoveal choroidal thickness, and
seven eyes (37%) demonstrated a decrease in subfoveal choroidal thickness at 6 month
follow-up. This is demonstrated pictorially in Figure 4.
Discussion
When the above data was analyzed including both the dry and nAMD patients there was a
statistically significant decrease in the subfoveal choroidal thickness over 6 months
compared to baseline (p=0.049). On subgroup analysis however, it was clear that the nAMD
patients, who made up the 61% of the cohort, drove this finding. The dry AMD patients did
not demonstrate a statistically significant decrease over 6 months when examined as a
subgroup. Although in both dry and nAMD groups there were some eyes that demonstrated
an increase in choroidal thickness over 6 months, there was overall a statistically significant
trend towards decreased choroidal thickness in the group considered as a whole. The
increase in subfoveal thickness, which was observed in both subgroups, may represent an
error intrinsic to manual measurements, or a natural variation in choroidal thickness. The
choroid is a highly vascular structure whose thickness varies with intraocular pressure,
perfusion pressure, nitric oxide production, and vasoactive substances such as circulating
catecholamines, and is believed to be highly sensitive to small vessel disease, therefore it
may be expected that there is some natural fluctuations of subfoveal choroidal thickness
over time.20-23. There is also known diurnal variation in choroidal thickness with the choroid
being thickness at night and thinnest during the day. A recent study by Chakraborty et al
demonstrated an average choroidal thickness of 0.256 +/− 0.049 mm with a diurnal
fluctuation of 0.029 +/− 0.016 mm. Patients included in this study had OCT imaging
performed at various times throughout the day and therefore there may be some choroidal
thickness variation due to differences when the measurements were taken.24 In normal eyes
on the Cirrus OCT, Manjunath et al. reported a subfoveal choroidal thickness of 272 ± 81μm
with a sample size of 34 subjects, and a mean age of 51.1 years (range, 22 to 78 years), as
well as demonstrating the reproducibility of choroidal thickness measurements by the same
technique described in this study, with strong inter-observer correlation r = 0.92, P < .
0001.17 Previous studies have demonstrated a 1.56 um decline in choroidal thickness per
year of life, and therefore based on the normative data obtained on the Cirrus HD-OCT by
Manjunath et al, the average choroidal thickness expected in normal patients with an
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average age of 78.5 years would be 229 um, which is significantly thicker than what was
observed in both the dry and nAMD cohorts in our study.17, 25
More recent work by the same group demonstrated a mean subfoveal choroidal thickness of
194.6 um (SD 88.4; n=40) in patients with nAMD vs. 213.4 um (SD 92.2; n=17) in patients
with dry AMD, with a mean age of 78.6 years.10 Our data demonstrates similar baseline
subfoveal choroidal thickness for patients with nAMD 182.8 +/− 77μm and dry AMD group
192.2 +/− 70μm, confirming that both the dry and nAMD patients have thinner than average
choroids compared to age-matched normal.
There are two hypotheses to explain the choroidal thinning observed in this investigation.
Patients with nAMD may have accelerated choroidal thinning due to vascular or metabolic
factors, which may contribute to the pathogenesis of AMD. Another possibility is that
treatment for nAMD, intravitreal anti-VEGF agents, may cause choroidal thinning.
VEGF is expressed in the retinal pigment epithelium of normal eyes where it is thought to
be a trophic factor for the choriocapillaris and play a role in choriocapillaris survival and
permeability. VEGF-A is a glycoprotein that is thought to have an important role in the
regulation of the choroidal vasculature.18, 26, 27
Therefore continuous VEGF blockage used in the treatment of nAMD through the use of
anti-VEGF agents, may negatively affect the maintenance of the choroid. Clinically it has
been demonstrated that retinal pigment epithelial cells undergo progressive atrophy in
patients in nAMD patients undergoing treatment with intravitreal anti-VEGF therapy,
although it is unclear if this is related to anti-VEGF treatment or the natural history of the
disease. 28,29
Rahman et al found no correlation between subfoveal choroidal thickness and treatment with
anti-VEGF agents, in a small case of 15 patients who were treated with 3 months of
intravitreal anti-VEGF medication and compared to 15 treatment naïve nAMD patients. Of
note, however this was a very small sample size, and choroidal thickness was not analyzed
over time.30 Conflicting data from Forte et al examined 34 patients with macular edema
injected with intravitreal bevacizumab. Retinal and choroidal thickness was measured before
and after one year of treatment, and in 24% of these patients, there was statistically
significant choroidal thinning at one-year follow-up, suggesting that VEGF blockade may
play a role in choroidal thinning.19
There are several limitations to this study. This examination did not sub-classify dry AMD
patients using AREDS criteria to assess disease severity, as the sample size was small and
the study was not powered to detect a difference in the sub cohorts of patients. It may be that
patients with more advanced dry AMD have a rate of decrease in subfoveal choroidal
thickness comparable to the nAMD group. Increased number of subjects with dry AMD
would be necessary to investigate this. Dry AMD also has a different clinical time course
than nAMD, so it may be that choroidal thinning does occur, but at a slower rate that would
not be significant over a 6 month study. Future studies employing long term follow up
would help elucidate choroidal thickness changes during the natural history of this disease
process.
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Another limitation is that with the Cirrus OCT, there is no way to be sure that the same
retinal location is scanned at differing time points. This issue may be exacerbated in patients
with poor fixation due to low vision. It is also difficult to determine the central foveal scan
in the setting of retinal edema or choroidal neovascularization. This may contribute to
choroidal thickness fluctuation that is unrelated to underlying disease process. In addition,
measurements were manually performed; automated software would be a more objective
evaluation of choroidal thickness.
In conclusion, this study suggests that there is a decrease in subfoveal choroidal thickness in
subjects with nAMD over 6 months that was not observed in those with dry AMD over the
same time period. It is unclear if this decrease represents the natural history of nAMD, or if
it is related to treatment with anti-VEGF agents. Continued advances in OCT technology,
such as choroidal segmentation, will allow for more accurate measurements of the choroid
in the future and hopefully aid in further understanding of the role of the choroid in disease
processes such as age-related macular degeneration.
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A-D: Graphical representation of the subfoveal choroidal thickness in subjects with age-
related macular degeneration (AMD) over six months with comparison to age matched
controls. Total of 49 eyes with AMD from 39 patients. 30 eyes (61%) had neovascular AMD
and 19 eyes (39%) had dry AMD at the start of the study.
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A-D: Choroidal thickness in a patient with dry AMD. [A,C] High definition Cirrus 1 line
raster scans and [B,D] color fundus photographs from a patient with a history of dry AMD
over 6 months.
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Choroidal thickness in a patient with neovascular AMD. [A,C] High definition Cirrus 1-line
raster scans and [B, D] color fundus photographs from a patient with a history of
neovascular AMD over 6 months.
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Scatterplot of the change in subfoveal choroidal thickness between baseline and 6 months in
neovascular AMD (A) and dry AMD (B) subgroups.
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Table 1
Subfoveal choroidal thickness in Age-related macular degeneration patients at baseline and at 6 months.
AMD Variant Subfoveal Choroidal Thickness (um) Total P Value
BASELINE 6 MONTHS
Dry 192.2+/− 69.91 190.8 +/− 60.27 19 eyes 0.824
Neovascular 182.8+/− 76.71 169.1+/−61.98 30 eyes 0.015
All ARMD 181.2 +/− 74.82 173.4+/−62.73 49 eyes 0.049
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